Welcome to the Working Group on New TB Drugs Blog
Future of Olive View TB Ward in Doubt
Los Angeles County is spending more than $16 million to build a dedicated tuberculosis ward that also could serve as a treatment center to isolate victims of a bioterrorism attack. But something’s missing: people to staff it.
This week in TB R&D – 22 June 2010
Last week, an analysis of product development partnerships (PDP) funding based on data from G-FINDER was published in the journal, International Health. The article praises successful PDPs as productive and cost-effective, while calling attention to their “increasingly important role as creators, developers and deliverers of new products for neglected diseases.”
Sign-on letter to UNITAID to release delayed TB funds
This sign-on letter was prepared by Lucy Cheshire, TB Advocacy Advisor, ACTION Project, Kenya. It calls on UNITAID to release grant funding to the Stop TB Partnership that has been “unnecessarily sidelined and/or delayed which threatens to exacerbate the spread of MDR-TB, derail the supply of paediatric drugs and undermine market shaping activities that are already underway or planned for both these crucial niches.”
World Bank Approves US$63.66 Million to Create Critical Public Health Laboratory Network in East Africa
WASHINGTON, May 25, 2010 — The World Bank’s Board of Executive Directors has approved US$63.66 million to create a unique regional network of 25 public health laboratories across Kenya, Tanzania, Uganda, and Rwanda. This network will operate across country borders, improving access to diagnostic services to vulnerable populations in cross border areas and making optimal use of internet and mobile communications to improve public health.
Launch of Grand Challenges Canada / Grands DĂ©fis Canada
Announcing the launch of Grand Challenges Canada / Grands DĂ©fis Canada – an innovative organization that will help redefine Canada’s role in the developing world by bringing together Canadian scientists, developing world scientific researchers, and the private sector to solve some of the most persistent health challenges facing poor countries.
North America’s Sole Manufacturer of MDR-TB Drugs Closing Its Doors
An Indiana drug maker that’s North America’s sole manufacturer of a multidrug-resistant tuberculosis drug is closing its doors after five years. The Purdue Research Foundation says the Chao Center for Industrial Pharmacy and Contract Manufacturing was unable to become self-sustaining in part because of the recession.
Interview with Stewart Cole
Stewart Cole helped create the Global Health Institute in 2007. Located at the Ecole polytechnique fĂ©dĂ©rale de Lausanne (EPFL), will use cutting-edge techniques to seek solutions to tuberculosis, a growing threat worldwide. Dr Cole’s work on tuberculosis, leprosy, AIDS, gas gangrene and bacterial molecular genetics is widely acclaimed throughout the world. He was a leading [...]
Funding a Global Health Fund
The fund that fights killer diseases such as TB and Aids needs to build on its success, but it is facing a fiscal crisis. World leaders will come together at the United Nations in September in order to accelerate progress towards the Millennium Development Goals (MDGs). Three of the eight MDGs involve bringing primary health services to the entire world’s population. A small amount of global funding, if well directed, could save millions of lives each year. The key step is to expand the Global Fund to Fight Aids, Tuberculosis, and Malaria into a Global Health Fund.
The UK Government Announces its First-Ever Grant to the Aeras Global TB Vaccine Foundation
Global efforts to combat tuberculosis gained momentum today when the government of the United Kingdom announced generous funding to the Aeras Global TB Vaccine Foundation.
This Week in TB R&D- 22 Feb 2010
A few recent reports track the progress being made by the Stop TB Partnership and TB research funding trends from 2005-2008. As global TB efforts increase in the areas of research, drug, vaccine and diagnostics development, greater emphasis has been placed upon funding.
